EPO Protein (His tag)

Catalog No. ABIN7535783

Product Details

Target: EPO (Erythropoietin (EPO))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: HEK-293 Cells

Purification tag / Conjugate: This EPO protein is labelled with His tag.

Purpose: Active Recombinant Human Erythropoietin/EPO Protein

Sequence: APPRLICDSR VLERYLLEAK EAENITTGCA EHCSLNENIT VPDTKVNFYA WKRMEVGQQA VEVWQGLALL SEAVLRGQAL LVNSSQPWEP LQLHVDKAVS GLRSLTTLLR ALGAQKEAIS PPDAASAAPL RTITADTFRK LFRVYSNFLR GKLKLYTGEA CRTGDR

Specificity: Ala28-Arg193

Purity: > 95 % by SDS-PAGE.

Sterility: 0.22 μm filtered

Endotoxin Level: <0.1EU/μg

Biological Activity Comment: 1.Measured by its binding ability in a functional ELISA. Immobilized Human EPO Protein at 5μg/mL (100 μL/well) can bind EPOR with a linear range of 0.12-23.83 ng/mL.|2.Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The ED₅₀ for this effect is 0.03-0.12 ng/mL.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid votex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1 % BSA, 5 % HSA, 10 % FBS or 5 % Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.

Buffer: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.

Storage: -20 °C,-80 °C

Storage Comment: Store the lyophilized protein at -20°C to -80°C for 12 months.|After reconstitution, the protein solution is stable at -20°C for 3 months, at 2-8°C for up to 1 week.

Target Details

Target: EPO (Erythropoietin (EPO))

Alternative Name: Erythropoietin/EPO (EPO Products)

Synonyms: EPO Protein, EP Protein, MVCD2 Protein, erythropoietin Protein, erythropoietin S homeolog Protein, erythropoietin a Protein, EPO Protein, epo Protein, epo.S Protein, Epo Protein, epoa Protein

Target Type: Hormone

Background:

Description: Erythropoietin is a member of the EPO / TPO family. It is a secreted, glycosylated cytokine composed of four alpha helical bundles. Erythropoietin can be found in the plasma and regulates red cell production by promoting erythroid differentiation and initiating hemoglobin synthesis. It also has neuroprotective activity against a variety of potential brain injuries and antiapoptotic functions in several tissue types. Erythropoietin is the principal hormone involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass. It is produced by kidney or liver of adult mammals and by liver of fetal or neonatal mammals. Genetic variation in erythropoietin is associated with susceptbility to microvascular complications of diabetes type 2. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. It has a longer circulating half-life in vivo. Erythropoietin is being much misused as a performance-enhancing drug in endurance athletes.

Name: EPO,EP,MVCD2

Gene ID: 2056

UniProt: P01588

Pathways: JAK-STAT Signaling, Hormone Activity, Negative Regulation of intrinsic apoptotic Signaling, Negative Regulation of Transporter Activity